Phase 1 Bladder Cancer Trial, Recruiting NCT07206225 Sponsor: Pfizer Condition: Bladder Cancer
Back to Bladder Cancer

Phase 1 Bladder Cancer Trial, Recruiting

NCT07206225
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older (or meet the minimum age required by local rules)
  • People who have been diagnosed with a specific type of early-stage bladder cancer — called high-risk, non-muscle invasive urothelial carcinoma — confirmed by a tissue sample, including a form called carcinoma in situ (CIS), which may or may not occur alongside other types of early tumour growth
  • People whose cancer has returned or not gone away after receiving at least 5 out of 6 doses of a standard BCG treatment course (a type of bladder cancer treatment)
  • People for whom surgery to remove the bladder (called radical cystectomy) has been refused, is not suitable, or is not considered appropriate by their medical team
  • People who have had a tumour tissue sample taken within the last 6 months
  • People with a general health rating of 0 or 1 on a standard medical scale, meaning they are either fully active or able to carry out light daily activities (confirm with trial site)

Who may not be able to join:

  • People currently receiving other cancer treatments for this type of bladder cancer, or who have had radiation therapy directed at the bladder in the past
  • People with significant kidney problems, liver problems, or certain blood abnormalities, as defined by the trial's specific measurements (confirm with trial site for exact thresholds)
  • People who have an active infection that is not currently under control, as defined by the trial's criteria (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
6 November 2025
Est. completion
29 January 2030

Where this trial is recruiting

🇫🇷 France 🇮🇱 Israel 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants only; Number of participants with adverse events (AEs) in Part 1 and Part 2 participants only; Number of participants with laboratory abnormalities in Part 1 and Part 2 participants only; Recurrence-free survival (RFS) in Part 3 participants only; Event-free survival (EFS) in Part 3 participants only

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov